Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Vor Biopharma (Nasdaq: VOR) is a clinical-stage cell and genome engineering company that is pioneering a novel approach to targeted cancer therapy. Their mission is to develop innovative treatments for patients with hematological malignancies by engineering hematopoietic stem cells (HSCs) to be treatment-resistant, thereby enabling more potent and effective targeted therapies. Vor Bio's lead product candidate, trem-cel (VOR33), consists of genome-edited HSCs that lack CD33, a protein commonly expressed on leukemia cells. This allows for targeted anti-CD33 therapies to be used post-transplant without harming the healthy new blood system. The company is leveraging its scientific expertise in HSC biology and genome editing to create a new paradigm in cancer care.
Serves as the central hub for research and development, clinical operations, corporate strategy, and administrative functions.
State-of-the-art laboratory facilities for advanced cell and genome engineering research, designed to support cutting-edge scientific discovery and process development. Proximity to world-class research institutions and a vibrant biotech talent pool.
A dynamic, collaborative, and patient-focused environment. The culture emphasizes scientific rigor, innovation, teamwork, and a shared commitment to developing transformative therapies for cancer patients. Employees are driven by a strong sense of purpose and the potential to make a significant impact.
The Cambridge headquarters is crucial for Vor Biopharma's operations, providing access to a rich ecosystem of scientific talent, research collaborations, and industry partners. It centralizes their R&D efforts and strategic decision-making.
While primarily based in the United States with its research and corporate hub in Cambridge, MA, Vor Biopharma's impact is global. The company engages in international clinical trials to evaluate its novel therapies, collaborates with research institutions and partners worldwide, and aims to bring its innovative treatments to cancer patients globally. Its strategic partnerships and clinical activities extend its operational reach beyond its physical locations.
100 Cambridgepark Drive, Suite 400
Cambridge
MA
USA
Address: 300 Cambridgepark Drive, Cambridge, MA 02140, USA
Expansion of R&D and operational capacity within the Cambridge biotech cluster, allowing for specialized functions and growth.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Vor Biopharma' leadership includes:
Vor Biopharma has been backed by several prominent investors over the years, including:
In the past 12 months, Vor Biopharma strengthened its executive leadership with a key appointment in the clinical development area, following a transition in the Chief Medical Officer role.
Discover the tools Vor Biopharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Vor Biopharma commonly uses the first initial followed by the last name for their email addresses. This is a frequent pattern in many biotech and pharmaceutical companies.
[first_initial][last]@vorbio.com
Format
jdoe@vorbio.com
Example
85%
Success rate
GlobeNewswire • May 9, 2024
Vor Biopharma announced its financial results for the first quarter of 2024 and provided updates on its clinical programs, including progress on trem-cel (VOR33) and VCAR33ALLO programs....more
GlobeNewswire • April 2, 2024
Vor Biopharma announced its participation and presentation at the 23rd Annual Needham Virtual Healthcare Conference, discussing its pipeline and corporate strategy....more
GlobeNewswire • March 5, 2024
Vor Biopharma reported its fourth quarter and full year 2023 financial results, along with a comprehensive update on its research and development activities and upcoming milestones....more
GlobeNewswire • June 20, 2023
Vor Biopharma announced the appointment of Eyal C. Attar, M.D., as its Chief Medical Officer, bringing extensive experience in oncology and hematology clinical development to the company....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Vor Biopharma, are just a search away.